Venus Medtech (Hangzhou) Inc. completed the enrollment of patients for a confirmatory clinical trial using its Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy (HCM), reaching 128 patients in 20 hospitals in mainland China since January 2021.
Siyi Intelligence Technology Co. Ltd. raised nearly $15 million in a series A funding round to speed up the development of its smart rehabilitation products and of its neurorehabilitation solutions and build a digital rehabilitation service platform.
Agilis Robotics Ltd. completed its first test in mainland China for use of its robotic instruments, which validated their feasibility and versatility for endoscopic surgery. After simulating training for endoscopic submucosal dissection and an en bloc resection of a bladder tumor, surgeons successfully used the surgical robot to remove the artificial tumor tissue. The test results met the expected goals.
Johnson & Johnson’s Biosense Webster division reported that its Qdot Micro diagnostic and ablation deflectable tip catheter secured approval for marketing in China from the National Medical Products Administration where options for treating arrhythmias are seeing growing demand. A radiofrequency (RF) ablation catheter, Qdot Micro reduced total ablation procedure time by nearly 90 minutes.
Europe has given device makers more time to meet requirements set out in the 2017 Medical Devices Regulation (MDR). The European Parliament approved in mid-February an extension of the transition periods for medical device and IVD manufacturers to comply with the new rules, which aim to enhance safety for patients and ensure the “smooth functioning of the internal market.”
Hygea Medical Technology Co. Ltd. has completed a series D funding round to develop an integrated platform for interventional oncology procedures and expand globally.
Bionicm Inc. completed a funding round on Feb. 13 to speed up development of its powered prosthetic leg products. The round, valued at “tens of millions of yuan,” was led by Nventure Capital, a wholly owned subsidiary of Nec Capital Solutions Ltd.
Shukun Technology Inc.’s recently approved AI-based system to assess coronary arteries can get results in minutes, significantly speeding up diagnostics.
Sciwind Biosciences Co. Ltd. started dosing in a phase III clinical trial in China of its ecnoglutide (XW-003) candidate in adults with type 2 diabetes, targeting patients who have not responded adequately to either metformin or changes in lifestyle.
